Founder Friendly Investors
Counsyl Surpasses 1 Million Genetic Screens - Pilot Growth Equity
Business Wire

Counsyl Surpasses 1 Million Genetic Screens

Counsyl, a genetic screening and counseling services company, today announced that more than one million of the company’s three premium genetic screens have been performed. By offering quick, accurate results with Foresight™ Carrier Screen, Prelude™ Prenatal Screen, and Reliant™ Cancer Screen, Counsyl has provided important information to people and families about reproductive health and hereditary cancer risk so they can make informed choices and plan for the future. This significant milestone illustrates the increasing recognition of the critical value of genetic screening in women’s health.

“As a doctor, I’m thrilled by this achievement because it means that patients have received crucial information that can help guide them in important decisions for themselves and their families,” said Dr. James Goldberg, chief medical officer at Counsyl. “While we continue to make incredible progress, we have a long way to go until women and their families are aware of the availability and utility of genetic screening, but I am confident that we will soon make this a routine part of patient care.”

Counsyl’s genetic screens and counseling services fulfill specific, personalized roles in patients’ healthcare needs. While each screen is tailored for a unique patient segment, Counsyl Complete™, our provider practice workflow solution, provides pre-test education, billing support, clear results reporting and on-demand genetic counseling.

Counsyl’s groundbreaking Foresight™ Carrier Screen was developed for couples who are planning to become pregnant and has identified more than 2,500 couples whose children have a significantly increased chance of being affected by an inherited disease. In fact, 86% of these couples would have been missed under conventional screening guidelines.

“What an incredible milestone! Thousands of physicians and hundreds of thousands of patients have chosen Counsyl at crucial life moments before and during pregnancy, and for cancer risk assessment. It’s the highest form of recognition we can imagine: our patients have trusted Counsyl now over a million times,” said Ramji Srinivasan, chief executive officer at Counsyl.

View full article